Brazil Launches Mass Dengue Vaccination Pilots Using Single-Dose Butantan Vaccine

Overview

• Maranguape begins on Saturday, Jan. 17, with a citywide Dia D and a drive‑thru site operating Jan. 17–30, offering Butantan‑DV for ages 15–59 and Takeda’s two‑dose vaccine for ages 10–14.
• Botucatu starts Sunday, Jan. 18, aiming to vaccinate about 90% of residents aged 15–59 across 28 posts open 8 a.m.–5 p.m., with photo ID, CPF and proof of residence required.
• Nova Lima opens vaccinations on Saturday, Jan. 17, at UBS clinics with extended hours, a roaming vacimóvel and scheduled drive‑thru sessions for eligible adults.
• The rollout uses Butantan‑DV, the first single‑dose dengue vaccine approved by Anvisa, with clinical trials showing nearly 75% efficacy against symptomatic disease, over 91% against severe cases and 100% against hospitalizations.
• Initial federal supply stems from a R$ 368 million contract for 3.9 million doses delivered to the public network, with Butantan projecting expanded deliveries through the second half of 2026.